Loading clinical trials...
Loading clinical trials...
Prospective Observational Multicenter Registry Study to Assess the Impact & Long-Term Outcomes of 68Ga-PSMA-11 PET/CT Imaging Evaluations for Patients With Prostate Cancer (Newly Diagnosed, Suspected Recurrence P or Are Candidates for Radioligand Therapy)
Conditions
Interventions
None- Observational
Locations
9
United States
Valley Urology
Fresno, California, United States
Urology Associates of Central California
Fresno, California, United States
Urological Associates of Western Colorado
Grand Junction, Colorado, United States
Idaho Urologic Institute
Meridian, Idaho, United States
Comprehensive Urology
Royal Oak, Michigan, United States
Urology Nevada
Reno, Nevada, United States
Start Date
January 30, 2025
Primary Completion Date
June 17, 2025
Completion Date
June 17, 2025
Last Updated
July 14, 2025
NCT07332000
NCT06616597
NCT07115914
NCT07407608
NCT07391982
NCT06862856
Lead Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions